Back

Optimized medical therapy enhances left atrial strain in HFrEF patients: a novel prognostic indicator

17 May 2025 (12:25 - 13:34)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - imaging (1) Imaging HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Rui Placido

CHULN and Faculty of medicine of the University of Lisbon, Lisbon (Portugal)

6 More presentations in this session

Presentation thumbnail
Obesity as a predictor of left ventricular dysfunction and heart failure in asymptomatic patients with type 2 diabetes mellitus
Professor S. Jovanova (Skopje, MK)
Abstract Slides Video
Presentation thumbnail
Right ventricle echocardiographic predictors of outcome in chronic heart failure
Doctor S. Antit (Tunis, TN)
Abstract Slides Video
Presentation thumbnail
Similarities of the effects of acute hyperglycaemia and acute ischemia on myocardial function
Professor G. Krljanac (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Left atrial reservoir strain in patients with acute decompensated heart failure with reduced and preserved left ventricular ejection fraction
Professor M. Samos (Martin, SK)
Abstract Slides Video
Presentation thumbnail
ABCDE-stress echocardiography with physical exercise: the impact of compensated chronic heart failure on the results and short-term prognosis
Doctor D. Abdulloev (Dushanbe, TJ)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - imaging (1)

The Event

Event poster

Heart Failure 2025

17 May 2025 12:25 CET
You may be interested in
thumbnail
Congress Presentation
Left atrial strain is influenced by cardiac resynchronisation therapy in advanced heart failure
thumbnail
Congress Presentation
Impact of optimized therapy on the evolution of patients with heart failure - reality of an advanced heart failure outpatient clinic of the unified health system
thumbnail
Congress Presentation
Cardiac left atrial evaluation and response in HFREF with sacubitril/valsartan: the CLEAR study.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources